Baker Botts advised Helmerich & Payne, while Latham & Watkins represented the initial purchasers in the offering. Helmerich & Payne, Inc. (NYSE: HP) has priced its...
Helmerich & Payne’s $550 Million Private Offering of Senior Notes
Quanta Services’ $2.7 Billion Acquisition of Blattner Energy
Latham & Watkins represented Quanta Services, Inc. in the transaction. Quanta Services, Inc. (NYSE: PWR) has entered into a definitive agreement to acquire Blattner Holding Company (Blattner),...
DraftKings’ Acquisition of Golden Nugget Online Gaming
Sullivan & Cromwell advised DraftKings, while White & Case advised Golden Nugget Online Gaming. Latham & Watkins LLP represented Tilman Fertitta and Fertitta Entertainment in the transaction....
HotelPlanner’s Merger with Reservations.com and Astrea Acquisition Corp.
Gunster Yoakley & Stewart and Latham & Watkins represented HotelPlanner, while Katz Teller Brant & Hild, LPA and Stradley Ronan Stevens & Young, LLP served as...
ECP Environmental Growth Opportunities Corp.’s $1.4 Billion Business Combination with Fast Radius
DLA Piper represented Fast Radius, while Latham & Watkins LLP represented ECP Environmental Growth Opportunities Corp. in the transaction. Fast Radius, Inc., a cloud manufacturing and...
Acropolis Infrastructure Acquisition Corp.’s $300 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Acropolis Infrastructure Acquisition Corp. (the Company) executed its initial public offering of 30,000,000 units at US$10...
Wallbox’s $1.5 Billion Merger with Kensington Capital Acquisition Corp. II
Latham & Watkins LLP and Loyens & Loeff represented Wallbox, while Cuatrecasas, Hughes Hubbard & Reed and Houthoff represented Kensington Capital Acquisition Corp. II in the...
eFFECTOR Therapeutics’ Merger with Locust Walk Acquisition Corp.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
Hyundai Motor Company and Kia Corporation’s Clearance For Investments in IonQ
Latham & Watkins LLP advised Hyundai Motor Company and Kia Corporation on the CFIUS clearance process. Hyundai Motor Company and Kia Corporation have received clearance from...
Decarbonization Plus Acquisition Corporation II’s Business Combination with Tritium
Vinson & Elkins LLP and Clifford Chance advised Decarbonization Plus Acquisition Corporation II on the business combination with Tritium Holdings Pty Ltd, represented by Corrs Chambers...
Bright Machines’ Merger with SCVX
Willkie Farr & Gallagher LLP represented SCVX in the transaction, while Latham & Watkins LLP and Wolf Theiss represented Bright Machines. SCVX (NYSE: SCVX), a special...
Science 37’s $1.05 Billion de-SPAC Transaction with LifeSci Acquisition II Corp.
Latham & Watkins LLP represented Science 37 in the transaction. Science 37, Inc. (Science 37), developer of the Decentralized Clinical Trial Operating SystemTM, and LifeSci Acquisition...